SEC Form 4 · accession 0000914475-15-000076

NEUROCRINE BIOSCIENCES INC · NBIX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Director

Period of report

Feb 10, 2015

Accepted (ET)

Feb 11, 2015 · 5:05 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000914475

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Feb 10, 2015	M	7,500	$4.76	A	298,062	D
Common Stock^F1	Feb 10, 2015	F	996	$35.83	D	297,066	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option	$4.76	Feb 10, 2015	M	7,500	D	Jun 28, 2008	May 28, 2015	Common Stock	7,500	0	D

F1The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 28, 2008, which, if unexercised, would have expired May 28, 2015. The option exercises are reported on Table II. These option exercises were pursuant to a net issuance arrangement effected under the issuer's equity incentive plan. The number of shares issued pursuant to the net issuance arrangement was calculated as follows: the option exercise price ($4.76) was subtracted from the February 10, 2015 market close price ($35.83) and this net amount ($31.07) was then multiplied by the number of options (7,500), with the resulting amount then divided by the market close price to result in a net issuance of 6,504 shares to the optionee. The 996 shares underlying the remaining portion of the options are not available for reissuance, and no shares are sold into the market as part of the exercise in connection with a net issuance program.